Cited by 88Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration Mechanisms

Activation of D1/D5 Dopamine Receptors Protects Neurons from Synapse Dysfunction Induced by Amyloid-β Oligomers

Open access
Jürgensen, Sofia, Antonio, Leandro L., Mussi, Gabriela E.A., Brito-Moreira, Jordano, Bomfim, Theresa R., De Felice, Fernanda G., Garrido-Sanabria, Emilio R., Cavalheiro, Ésper A. +1 more·2011·Journal of Biological Chemistry

Abstract

Soluble oligomers of the amyloid-β peptide (AβOs) accumulate in the brains of Alzheimer disease (AD) patients and are implicated in synapse failure and early memory loss in AD. AβOs have been shown to impact synapse function by inhibiting long term potentiation, facilitating the induction of long term depression and inducing internalization of both AMPA and NMDA glutamate receptors, critical players in plasticity mechanisms. Because activation of dopamine D1/D5 receptors plays important roles in memory circuits by increasing the insertion of AMPA and NMDA receptors at synapses, we hypothesized that selective activation of D1/D5 receptors could protect synapses from the deleterious action of AβOs. We show that SKF81297, a selective D1/D5 receptor agonist, prevented the reduction in surface levels of AMPA and NMDA receptors induced by AβOs in hippocampal neurons in culture. Protection by SKF81297 was abrogated by the specific D1/D5 antagonist, SCH23390. Levels of AMPA receptor subunit GluR1 phosphorylated at Ser(845), which regulates AMPA receptor association with the plasma membrane, were reduced in a calcineurin-dependent manner in the presence of AβOs, and treatment with SKF81297 prevented this reduction. Establishing the functional relevance of these findings, SKF81297 blocked the impairment of long term potentiation induced by AβOs in hippocampal slices. Results suggest that D1/D5 receptors may be relevant targets for development of novel pharmacological approaches to prevent synapse failure in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m110.177790

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Receptor downregulation has been extended to other plasticity-associated receptors, including EphB2 receptors, AMPA receptors, and insulin receptors.

    “Receptor downregulation has been extended to other plasticity-associated receptors, including EphB2 receptors (Lacor et al., 2007), AMPA-Rs (Jurgensen et al., 2011; Zhao et al., 2010), and insulin Rs (Zhao et al., 2008).”
  • A connection has recently been established between dopaminergic signaling and Alzheimer's disease, with demonstration that selective activation of D1/D5 dopamine receptors prevents pathological changes in synapse composition and function, including inhibition of LTP, induced by Aβ oligomers.

    “a connection has recently been established between dopaminergic signaling and AD, with demonstration that selective activation of D1/D5 dopamine receptors prevents pathological changes in synapse composition and function (including inhibition of LTP) induced by Aβ oligomers (Jurgensen et al., 2011).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 61 · Cited by 88

Research works printed but not linked: 5

  1. [4]4. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., Wals, P., Zhang, C., Finch, C. E., Krafft, G. A., and Klein, W. L. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 6448-6453
  2. [29]29. Vitolo, O. V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O., and Shelanski, M. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 13217-13221
  3. [47]47. He, K., Song, L., Cummings, L. W., Goldman, J., Huganir, R. L., and Lee, H. K. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 20033-20038
  4. [58]58. Yang, Y., Wang, X. B., Frerking, M., and Zhou, Q. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 11388-11393
  5. [59]59. Man, H. Y., Sekine-Aizawa, Y., and Huganir, R. L. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 3579-3584

Authors
Jürgensen, S., Antonio, L. L., Mussi, G. E. A., Brito-Moreira, J., Bomfim, T. R., De Felice, F. G., Garrido-Sanabria, E. R., Cavalheiro, É. A., & Ferreira, S. T.
Affiliations
  • Universidade Federal do Rio de Janeiro (BR)
  • The University of Texas System (US)
  • Universidade Federal de São Paulo (BR)
Corresponding author
Ferreira, Sergio T.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2011-02
Volume
286
Issue
5
Pages
3270-3276
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2029181104
Cited by
88
References
61
Citations by year
2026: 2 · 2025: 7 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 10 · 2018: 7 · 2017: 8 · 2016: 7 · 2015: 11 · 2014: 2 · 2013: 9 · 2012: 7
FWCI
4.11
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Americanae (AECID Library) (submittedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
Funders
  • Fundação Oswaldo Cruz
  • National Institutes of Health (5sc1ns063950-04)
  • National Institute of Neurological Disorders and Stroke (SC1 NS063950, 3SC1NS063950-03S1, 5SC1NS063950-04)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
dopamine D1/D5 receptors, amyloid-beta oligomers, Alzheimer's disease, synaptic dysfunction, AMPA receptors, NMDA receptor, GluR1 phosphorylation, calcineurin, long-term potentiation, long-term depression, hippocampal neurons, SKF 81297, SCH 23390, receptor internalization, synaptic plasticity
MeSH terms
Animals, Benzazepines, Cells, Cultured, Hippocampus, Humans, Memory, Neurons, Synapses, Receptors, N-Methyl-D-Aspartate, Amyloid beta-Peptides, Receptors, Dopamine D1, Receptors, AMPA, Protective Agents, Receptors, Dopamine D5, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review